Ballentine Partners LLC bought a new position in Laboratory Co. of America Holdings (NYSE:LH – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,112 shares of the medical research company’s stock, valued at approximately $249,000.
A number of other hedge funds have also recently modified their holdings of LH. Wealth Enhancement Advisory Services LLC lifted its position in shares of Laboratory Co. of America by 3.4% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,581 shares of the medical research company’s stock valued at $3,622,000 after acquiring an additional 550 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in Laboratory Co. of America by 9.3% during the first quarter. Valeo Financial Advisors LLC now owns 7,823 shares of the medical research company’s stock worth $1,709,000 after buying an additional 666 shares in the last quarter. First Trust Direct Indexing L.P. lifted its position in Laboratory Co. of America by 2.4% during the first quarter. First Trust Direct Indexing L.P. now owns 4,291 shares of the medical research company’s stock worth $937,000 after buying an additional 100 shares in the last quarter. Tempus Wealth Planning LLC lifted its position in Laboratory Co. of America by 8.9% during the first quarter. Tempus Wealth Planning LLC now owns 1,616 shares of the medical research company’s stock worth $353,000 after buying an additional 132 shares in the last quarter. Finally, AMI Asset Management Corp lifted its position in Laboratory Co. of America by 3.0% during the first quarter. AMI Asset Management Corp now owns 217,698 shares of the medical research company’s stock worth $47,558,000 after buying an additional 6,340 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.
Laboratory Co. of America Stock Performance
NYSE LH opened at $228.09 on Wednesday. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $222.68 and its two-hundred day moving average is $212.75. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $239.50. The stock has a market capitalization of $19.15 billion, a price-to-earnings ratio of 44.12, a PEG ratio of 1.77 and a beta of 1.05.
Laboratory Co. of America Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.26%. The ex-dividend date is Tuesday, November 26th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.
Analyst Upgrades and Downgrades
LH has been the topic of a number of research analyst reports. StockNews.com downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Piper Sandler lifted their target price on Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft lifted their target price on Laboratory Co. of America from $220.00 to $230.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Jefferies Financial Group lifted their price objective on Laboratory Co. of America from $245.00 to $265.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, Robert W. Baird lifted their price objective on Laboratory Co. of America from $282.00 to $289.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Laboratory Co. of America currently has an average rating of “Moderate Buy” and a consensus price target of $253.92.
Check Out Our Latest Report on Laboratory Co. of America
Insider Buying and Selling at Laboratory Co. of America
In other Laboratory Co. of America news, EVP Lance Berberian sold 12,093 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $229.10, for a total transaction of $2,770,506.30. Following the transaction, the executive vice president now owns 15,921 shares of the company’s stock, valued at $3,647,501.10. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Lance Berberian sold 12,093 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $229.10, for a total value of $2,770,506.30. Following the transaction, the executive vice president now directly owns 15,921 shares of the company’s stock, valued at approximately $3,647,501.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the director now directly owns 13,722 shares in the company, valued at $3,156,060. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,679 shares of company stock worth $6,946,306. 0.85% of the stock is owned by insiders.
About Laboratory Co. of America
Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
See Also
- Five stocks we like better than Laboratory Co. of America
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- How is Compound Interest Calculated?
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- How to Read Stock Charts for Beginners
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.